Bruker (NASDAQ:BRKR) Sets New 12-Month Low – What’s Next?

Bruker Co. (NASDAQ:BRKR) shares hit a new 52-week low on Thursday . The stock traded as low as $47.44 and last traded at $48.67, with a volume of 297008 shares. The stock had previously closed at $50.50.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of analyst reports. TD Cowen decreased their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Guggenheim reissued a “buy” rating on shares of Bruker in a report on Monday. Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Barclays decreased their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, Bank of America upped their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Stock Performance

The company has a fifty day moving average price of $56.39 and a two-hundred day moving average price of $59.81. The company has a market capitalization of $7.36 billion, a P/E ratio of 63.85, a PEG ratio of 2.16 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.41%. Bruker’s payout ratio is 26.32%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker in the fourth quarter valued at approximately $234,000. EDENTREE ASSET MANAGEMENT Ltd lifted its position in shares of Bruker by 11.2% during the 4th quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company’s stock valued at $9,262,000 after acquiring an additional 15,900 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bruker by 17.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company’s stock worth $20,926,000 after acquiring an additional 52,214 shares in the last quarter. Voloridge Investment Management LLC grew its holdings in Bruker by 179.6% in the fourth quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 12,145 shares during the period. Finally, Two Sigma Advisers LP increased its stake in Bruker by 406.1% in the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company’s stock valued at $8,248,000 after purchasing an additional 112,900 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.